Hamlet BioPharma featured at MSQ’s CEO Webinar series released during the JP Morgan Health Care Conference 2024
Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along with an extensive project and patent portfolio, is delighted to announce the webinar, hosted by MSQ ventures in the MSQ’s CEO Webinar series, released during the JP Morgan Health Care Conference 2024, this week.
|
|
|
|
Register in advance for this webinar:
|
|
MSQ Ventures and BioAroundWorld are collaborating to host a bi-weekly MSQ CEO Webinar Series targeting strategic partners and financial investors from the global-regional biopharma community. The webinar aims to promote knowledge-sharing and networking among participants by featuring CEOs who will present their companies' clinical pipeline's value proposition, differentiation, and upcoming milestones. The primary objective of the webinar is to enhance the visibility of participating companies fostering global-regional biopharma collaborative opportunities.
About Hamlet Biopharma
Hamlet Biopharma is an innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections. The company is listed on Spotlight Stockmarket in Stockholm, Sweden, under the ticker HAMLET.
Read more about the company and the portfolio of drug candidates at www.hamletbiopharma.com.
For further information, please contact:
Catharina Svanborg, Chairman and Founder of Hamlet BioPharma, +46-709 42 65 49
catharina.svanborg@hamletpharma.com
Martin Erixon, CEO Hamlet BioPharma, +46-733 00 43 77
martin.erixon@hamletpharma.com